DUB

IU1-47 是一种特异性 USP14抑制剂，IC50为 0.6 μM。它诱导培养的神经元中 tau 蛋白降解。它抑制 IsoT/USP5， IC50为 20 μM。

HBX 19818 is a specific ubiquitin-specific protease 7 (USP7) inhibitor (IC50: 28.1 μM).

C527 is a is a pan DUB enzyme inhibitor. Which has a high potency for the USP1/UAF1 complex (IC50=0.88 μM).

GRL0617 is a selective and competitive SARS-CoVPLpro and deubiquitinase noncovalent inhibitor(IC50 : 0.6 μM, Ki : 0.49 μM).

MF-094 is a selective USP30 inhibitor with IC50 of 0.12 μM. MF-094 can increase protein ubiquitination and accelerate mitophagy.Cost-effective and quality-assured.

MS7131 is a DUBTAC inhibitor that recruits USP1. It effectively reduces histone H3 lysine 27 trimethylation and significantly inhibits the proliferation and colony-forming ability of cancer cells.

G13KS: UCHL1 ligand, deubiquitinase inhibitor; reduces monoubiquitin in glioblastoma cells.

JAMM inhibitor 2 targets thrombin, Rpn11, MMP2 with IC50s 10, 46, 89 μM, aids cancer research.

USP7-IN-10 hydrochloride, also known as compound 1, is a potent inhibitor of the enzyme ubiquitin-specific protease 7 (USP7), exhibiting an IC50 value of 13.39

GK16S, a UCHL1 chemogenomic probe, serves as a complementary tool to GK13S for the investigation of UCHL1 function in cellular studies [1].

UBD1031 exhibits strong affinity for the ubiquitin-binding domain (UBD) of USP16, with a dissociation constant (KD) of 48 nM. It inhibits the interaction between USP16 and ISG15, displaying an effective concentration (EC50) of 1.7 nM. UBD1031 can serve as a chemical probe for investigating USP16 UBD.

Subquinocin is a CYLD inhibitor that suppresses deubiquitinating enzymes (DUB) of the USP family. By inhibiting CYLD, Subquinocin enhances the activation of the NF-κB and IFN pathways. Additionally, Subquinocin facilitates the activation of IRF3 and/or IRF7 in the RIG-I-mediated interferon pathway.

A unique collection of xnum ubiquitination related small chemicals can be used for high throughput and high content screening；

OTUB2-IN-1 is an OTUB2 inhibitor with antitumor activity and can be used to study skin cancer and non-small cell lung cancer (NSCLC).

OTUB1/USP8-IN-1 HCL is a potent dual inhibitor of OTUB1 and USP8 with potential antitumour activity, inhibiting both OTUB1 and USP8 for leukaemia

USP7-IN-15 (compound J21) is an inhibitor of USP7, exhibiting an IC50 value of 41.35 ± 2.16 nM.

(R)-CMPD-39 is the R-enantiomer of CMPD-39. CMPD-39 acts as a selective non-covalent inhibitor of the ubiquitin-specific protease USP30 with an IC50 of approximately 20 nM and demonstrates high selectivity for other DUB family members at concentrations ranging from 1-100 μM. By inhibiting USP30's deubiquitination activity, CMPD-39 enhances the ubiquitination of mitochondrial proteins TOMM20 and SYNJ2BP and promotes the accumulation of phosphorylated ubiquitin. This process accelerates both mitophagy and pexophagy. Additionally, CMPD-39 significantly restores impaired mitochondrial function in dopaminergic neurons derived from Parkinson’s disease patients.

USP8-IN-2 is a potent inhibitor of the deubiquitinating enzymes USP7 and USP8, with an IC50 of 4.0 μM against USP8D.

USP8-IN-3 is a potent inhibitor of the deubiquitinating enzymes USP7 and USP8, with IC50 of 4.0 μM against USP8D.

USP7-IN-16 (Compound 61) is a selective inhibitor of USP7, with IC50 values of 5.5 nM in the FLINT assay and 2.1 nM in MM.1S cells. This compound exhibits antitumor activity in mice and holds potential for research in the field of oncology.

T20-M is a precursor peptide with strong binding affinity for UBE2C.

EN523 targets non-catalytic allosteric cysteine C23 in K48 ubiquitin-specific deuquitinase OTUB1.

USP7Ligand-Linker Conjugates 1 is a Target Protein Ligand-Linker Conjugate comprising a USP7 ligand and a PROTAC linker, capable of recruiting E3 ligase. It is utilized in the synthesis of PROTACUSP7 Degrader-1.

BAY-728 serves as a negative control for BAY-805, a potent and selective inhibitor of USP21 [1].

Ga-CY03 (compound) is a FAP-tracing molecule designed based on the FAP inhibitor QI-18 and labeled with [Ga].

Q14 is a polypeptide derived from the transmembrane (TM) domain of USP30 (ubiquitin specific peptidase30) and is capable of inhibiting the deubiquitination activity of USP30 (IC50=57.2 nM). By hindering the interaction between USP30’s transmembrane and catalytic domains, it lowers USP30 activity. The Q14 polypeptide contains an LC3 interaction region (LIR) motif, enabling it to bind with LC3, thereby accelerating autophagosome formation and promoting mitophagy. Q14 is applicable in the study of neurodegenerative diseases, mitochondrial quality control, and cellular metabolism.

USP8-IN-1 is an inhibitor of USP8 with an IC 50 of 1.9 μM. USP8-IN-1 inhibits H1975 cell growth with a GI 50 of 82.04 μM [1].

STD1T is a USP2a inhibitor with anticancer activity that reduces levels of the cell cycle protein D1 protein in HCT116 colon cancer cells.

EOAI3402143 inhibits Usp9x and Usp24 activity, increases tumor cell apoptosis.

Benzamide, 4-[6-amino-4-ethyl-5-(4-hydroxyphenyl)-3-pyridinyl]-N-methyl- is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM.

SJB2-043 is an inhibitor of USP1-UAF1 ( IC50 : 544 nM).

Dub-in-2, with an IC50 value of 0.28 for USP8, is an effective deubiquitinase inhibitor.

NSC-632839 (Ubiquitin Isopeptidase Inhibitor II) is a nonselective isopeptidase inhibitor, which inhibits USP2 (EC50: 45±4 μM), USP7 (EC50: 37±1 μM), and SENP2

DUB-IN-1, with an IC50 value of 0.24 for USP8, is an active inhibitor of ubiquitin-specific protease (USPs).

USP7/USP47 inhibitor (USP7/47 inhibitor-1) is a selective ubiquitin-specific protease 7/47 (USP7/USP47) inhibitor, with EC50s of 0.42 μM and 1.0 μM,

XL177A is a selective irreversible USP7 inhibitor(IC50 : 0.34 nM). XL177A elicits cancer cell killing through a p53-dependent mechanism.

USP25/28 inhibitor AZ1 is a selective, orally active and non-competitive dual ubiquitin-specific protease USP25/28 inhibitor.Cost-effective and quality-assured.

P 22077 (P22077) is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM. It also inhibits the closely related USP47.

STAMBP-IN-1 is a novel selective antagonist of deubiquitinase STAM-binding protein (STAMBP), decreasing NALP7 protein levels and suppressing IL-1β release after

P005091 (P5091) is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM.

VLX1570 is a competitive inhibitor of proteasome DUB activity with IC50 ranging from 4.2 uM to 8.6 uM. It has potent inhibition for USP14.

ML323 is a reversible and effective USP1-UAF1 inhibitor in a Ub-Rho assay and in orthogonal gel-based assays using K63-linked di-Ub and Ub-PCNA as substrates.

GNE-6640: non-covalent USP7 inhibitor; IC50s: 0.75 µM (full), 0.43 µM (catalytic), 20.3 µM (USP43), 0.23 µM (Ub-MDM2).

DUB-IN-3 is a potent deubiquitinase (USP) enzyme inhibitor and the IC50 for USP8 is 0.56 μM.

ML364 is an inhibitor of ubiquitin specific peptidase 2 (USP2) and can be used for the research of breast cancer.

IU1-248 is a derivative of IU1. IU1-248 is a potent and selective USP14 inhibitor with an IC50 of 0.83 μM[1].

GNE-6776 is a selective USP7 inhibitor.

TCID (UCH-L3 Inhibitor)(IC50=0.6 μM) is a DUB inhibitor of ubiquitin C-terminal hydrolase L3. It has the 125-fold selectivity to L1.

USP1-IN-2 is a potent USP1 inhibitor with potential anti-tumor activity for the study of cancer.

POSH-IN-1 (Compound 108) is an inhibitor of the POSH polypeptide （e3 ligase) and has antiviral, anticancer, and neurodegenerative disease potential.